An algorithm for the care of type 2 diabetes

Critical Pathways in Cardiology

Volumn 8, Issue 4, 2009, Pages 156-165

  Cole, Alan ^a   Nathan, David M ^b   Savaria Porter, Elizabeth ^c   Copeland, Paul ^b   Turchin, Alexander ^a   Brunt, Melanie ^d,e   Zusman, Randall ^b   Barrett, Jo Ann ^c   Wexler, Deborah ^b   Case, Emily ^a   McMahon, Graham T ^a   Mort, Elizabeth ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Partners Community HealthCare Inc   (United States)

^d Harvard Medical School ^*  (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Hypertension; Insulin management; Management of hyperlipidemia; Type 2 diabetes

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; EXENDIN 4; FIBRIC ACID DERIVATIVE; FISH OIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLYSEL; HIGH DENSITY LIPOPROTEIN; INFLUENZA VACCINE; INSULIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN; METFORMIN; MIGLITOL; NATEGLINIDE; NICOTINIC ACID; PHENFORMIN; PIOGLITAZONE; PNEUMOCOCCUS VACCINE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; CREATININE URINE LEVEL; DEPRESSION; DIABETES CONTROL; DIABETES EDUCATION; DIABETIC PATIENT; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG INDICATION; DRUG WITHDRAWAL; EDEMA; EYE EXAMINATION; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INFLUENZA; INSULIN TREATMENT; KIDNEY FAILURE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SELF CARE; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ADULT; ALGORITHMS; CARDIOVASCULAR DISEASES; CRITICAL PATHWAYS; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY; UNITED STATES;

EID: 75949096937     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e3181c017e2     Document Type: Review

References (19)

1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Clin Diabetes. 2009;27:4-16.
2. Standards of Medical Care in Diabetes-2009. Diabetes Care. 2009;32:S13-S61.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2006;106:3143.
4. Chobanian AV, Bakris JL, Black HR, et al. Seventh report of the joint national committee on the prevention, detection, evaluation and treatment of high blood pressure. Hypertionsion. 2003;42:1206-1252.
5. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorthiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
6. The International Expert Committee. International expert committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1-8.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
8. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.
9. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703-713.
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of both macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ. 1998;317:713-720.
12. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
13. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358: 2545-2559.
14. The ADVANCE Collaborative Group. Intensive Blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358: 2560-2572.
15. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360: 129-139.
16. Holstein A, Stumvoll M. Contraindications can damage your health: is metformin a case in point? Diabetologia. 2005;48:2454-2459.
17. Nesto R, Bell D, Bonow R, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108: 2941-2948.
18. Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44:751-755.
19. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.